drugset
drugset / Trial / NCT04652219

CART Therapy in GUCY2C-positive Digestive Tract Tumors

NCT04652219 ↗

Phase 0 Completed 1 enrolled Weijia Fang, MD Innovative Cellular Therapeutics Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment

Summary

Ict-gc is an open, single-center study to evaluate the safety and efficacy of CAR-T-targeted therapy in patients with advanced gastrointestinal tumors.

Timeline

Start
2020-10-10
Primary completion
2021-10-09
Completion
2021-10-09

Drugs

EvaluationDrugModalityDoseRoute
Subject gucy2c cart cells Cell therapy — —

Indications

digestive system cancer